Hims & Hers FDA Warning Over Deceptive GLP-1 Marketing

In 2025, the Food and Drug Administration (FDA) issued a formal warning to Hims & Hers Health over marketing practices involving GLP-1 weight loss medications. The agency found that certain promotional materials created the impression that compounded GLP-1 drugs were the same as FDA-approved medications such as semaglutide or tirzepatide.

Due to overwhelming demand and supply shortages, many telehealth platforms have offered compounded versions through partner pharmacies. These compounded drugs are not reviewed by the FDA for safety or effectiveness in the same way as branded medications.

What the FDA Objected to in the Hims & Hers Marketing

The FDA’s warning for Hims & Hers focused on how compounded GLP-1 products were being promoted. Marketing language implied that patients were receiving the same drugs used in major clinical trials, without clearly disclosing that these were non-approved compounded versions.

Regulators emphasized that companies must clearly communicate when a product is not FDA-approved and cannot claim clinical benefits associated with approved drugs unless supported by proper evidence.

Compounded drugs may vary in potency and purity, and side effects may not be tracked as closely as they are for approved medications. If something goes wrong, patients may not have the same safety data available to guide medical responses.

This kind of marketing also undermines public trust in healthcare systems and telehealth platforms. Consumers expect transparency, especially when dealing with prescription medications and weight-loss treatments that affect long-term health.

Potential Legal Claims for Consumers

When companies market drugs in a deceptive manner, affected individuals may have legal rights under state consumer protection laws and unfair competition statutes. If a person relied on misleading advertising and suffered harm, they may be able to pursue claims.

The Lyon Firm represents individuals harmed by misleading pharmaceutical and health product marketing. Our firm focuses on cases where companies fail to disclose important safety information or promote drugs in a way that distorts the truth.

The Lyon Firm can help clients understand how deceptive GLP-1 marketing may have impacted their treatment decisions and pursue compensation where appropriate. Our attorneys work with medical and regulatory experts to analyze how marketing practices affected patient safety and financial harm.

The Lyon Firm offers free and confidential consultations and handles cases on a contingency basis, meaning clients pay nothing unless compensation is recovered.